Fluocinolone Implant Real-World Experience Matches DME Trials
11/17/2020
A fluocinolone acetonide implant (Iluvien) administered under real-world circumstances works just as well for diabetic macular edema (DME) as it did in clinical trials, a new study suggests, Medscape reports.
Patients who had not benefited from anti-vascular endothelial growth factor (anti-VEGF) intravitreal injections experienced improved vision and sustained it for 3 years.
The results show the advantages of an implant over monthly injections, said Ramin Khoramnia, MD, PhD, from the University Eye Clinic in Heidelberg, Germany. With this approach, “all these problems of adherence and compliance are really not an issue,” he told Medscape Medical News.